{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:22:31Z","timestamp":1753888951159,"version":"3.41.2"},"reference-count":20,"publisher":"Archives of Endocrinology and Metabolism","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,21]]},"DOI":"10.20945\/2359-3997000000654","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T13:03:33Z","timestamp":1687784613000},"source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival"],"prefix":"10.20945","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3671-4147","authenticated-orcid":false,"given":"Mariana","family":"Ornelas","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-3751","authenticated-orcid":false,"given":"Marta","family":"Borges-Canha","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-8771","authenticated-orcid":false,"given":"Pedro","family":"Gouveia","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-0803","authenticated-orcid":false,"given":"Margarida","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5602-1239","authenticated-orcid":false,"given":"Eduarda","family":"Resende","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6444-1428","authenticated-orcid":false,"given":"Maritza","family":"S\u00e1","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-6867","authenticated-orcid":false,"given":"Silvestre","family":"Abreu","sequence":"additional","affiliation":[]}],"member":"8510","reference":[{"issue":"2","key":"key20230626090309_B1","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley","year":"2021","unstructured":"1 Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021;21(2):e212-22.","journal-title":"Clin Med (Lond)"},{"issue":"9","key":"key20230626090309_B2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","unstructured":"2 Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-80.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"key20230626090309_B3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","unstructured":"3 Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020;8(2):e000779.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"key20230626090309_B4","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4158\/EP12280.GL","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association [published correction appears in Endocr Pract. 2013 Jan-Feb;19(1):175]","volume":"18","author":"Garber","year":"2012","unstructured":"4 Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association [published correction appears in Endocr Pract. 2013 Jan-Feb;19(1):175]. Endocr Pract. 2012;18(6):988-1028.","journal-title":"Endocr Pract"},{"issue":"4","key":"key20230626090309_B5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","unstructured":"5 Kahaly GJ, Bartalena L, Heged\u00fcs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-86.","journal-title":"Eur Thyroid J"},{"issue":"2","key":"key20230626090309_B6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","unstructured":"6 Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-89.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key20230626090309_B7","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Fleseriu","year":"2016","unstructured":"7 Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(11):3888-921.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20230626090309_B8","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021 [published correction appears in Diabetes Care. 2021 Sep;44(9):2182]","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"8 American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021[published correction appears in Diabetes Care. 2021 Sep;44(9):2182]. Diabetes Care. 2021;44(Suppl 1):S15-33.","journal-title":"Diabetes Care"},{"journal-title":"Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute","author":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5","key":"key20230626090309_B9","unstructured":"9 Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed on: 11th Oct 2022."},{"issue":"7","key":"key20230626090309_B10","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1210\/clinem\/dgac161","article-title":"Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study","volume":"107","author":"Labadzhyan","year":"2022","unstructured":"10 Labadzhyan A, Wentzel K, Hamid O, Chow K, Kim S, Piro L, et al. Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study. J Clin Endocrinol Metab. 2022;107(7):1976-82.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20230626090309_B11","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","unstructured":"11 Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"key20230626090309_B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000518619","article-title":"Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma","volume":"11","author":"Ng","year":"2021","unstructured":"12 Ng KYY, Tan SH, Tan JJE, Tay DSH, Lee AWX, Ang AJS, et al. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2021;11(1):9-21.","journal-title":"Liver Cancer"},{"issue":"7","key":"key20230626090309_B13","doi-asserted-by":"crossref","first-page":"437.e1","DOI":"10.1016\/j.urolonc.2021.01.006","article-title":"Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors","volume":"39","author":"Ma","year":"2021","unstructured":"13 Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, et al. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Urol Oncol. 2021;39(7):437.e1-e9.","journal-title":"Urol Oncol"},{"issue":"1","key":"key20230626090309_B14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","unstructured":"14 Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"key20230626090309_B15","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors","volume":"70","author":"Zhong","year":"2021","unstructured":"15 Zhong L, Wu Q, Chen F, Liu J, Xie X. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother. 2021;70(9):2559-76.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"key20230626090309_B16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","unstructured":"16 Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87.","journal-title":"BMC Med"},{"issue":"4","key":"key20230626090309_B17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/cancers13040860","article-title":"Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors","volume":"13","author":"Paderi","year":"2021","unstructured":"17 Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L, et al. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2021;13(4):860.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"key20230626090309_B18","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","unstructured":"18 Cheung YM, Wang W, McGregor B, Hamnvik OR. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;71(8):1795-812.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"key20230626090309_B19","doi-asserted-by":"crossref","first-page":"e1742","DOI":"10.1002\/onco.13868","article-title":"Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors","volume":"26","author":"Martini","year":"2021","unstructured":"19 Martini DJ, Goyal S, Liu Y, Evans ST, Olsen TA, Case K, et al. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2021;26(10):e1742-50.","journal-title":"Oncologist"},{"issue":"1","key":"key20230626090309_B20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","unstructured":"20 Jia XH, Geng LY, Jiang PP, Xu H, Nan KJ, Yao Y, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39(1):284.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T13:03:49Z","timestamp":1687784629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/immune-checkpoint-inhibitor-induced-endocrinopathies-a-possible-indicator-of-improved-survival\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,21]]}},"alternative-id":["10.20945\/2359-3997000000654"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000654","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e000654"}}